Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ...

Retrieved on: 2023-09-14 15:03:33

Tags for this article:

Click the tags to see associated articles and topics

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of .... View article details on HISWAI: https://pipelinereview.com/index.php/2023091484216/Antibodies/Q32-Bio-and-Horizon-Therapeutics-plc-Announce-Dosing-of-First-Patient-in-Phase-2-Trial-of-Bempikibart-formerly-ADX-914-for-Severe-Alopecia-Areata.html

Excerpt

“Bempikibart represents a potential unique approach to correcting immune system dysregulation in this and other diseases.” “IL-7 is involved in ...

Article found on: pipelinereview.com

View Original Article